The Effects of Intraperitoneal Dexmedetomidine in Comparison With Ropivacaine in Postoperative Pain After Laparoscopic Sleeve Gastrectomy: A Double-Blind, Randomized, Placebo-Controlled, Clinical Trial Publisher



Neishaboury M¹ ; Shokri S¹ ; Kianpour P² ; Farhadi K² ; Najjari K³ ; Sharifnia H¹ ; Mohammadyousef R⁴ ; Khajavi M¹ Show Affiliations
Source: Obesity Surgery Published:2025

Abstract

Background: Studies have shown that non-opioid analgesic drugs can reduce the pain of patients after bariatric surgery. Ropivacaine and dexmedetomidine are associated with high efficacy and safety in managing postoperative complications. We evaluated the effectiveness of ropivacaine alone and in combination with dexmedetomidine in improving outcomes after sleeve gastrectomy surgery. Methods: This double-blind, randomized clinical trial, included patients undergoing bariatric surgery in 2022 and 2023. The participants were randomly divided into three groups: treated with ropivacaine alone (group A), ropivacaine and dexmedetomidine combination (group B), or normal saline (group C). Pain scores, morphine consumption, and postoperative nausea and vomiting (PONV) were assessed over 24 h. Results: All groups showed reduced pain, but group B had significantly lower VAS scores than groups A and C at 4–24 h postoperatively, with the highest difference achieved by group B compared to control at 12-h time point (β = − 2.5, P < 0.001). Morphine use was lowest in group B (4.38 ± 1.24 mg vs. 6.04 ± 2.07 mg in group A and 7.50 ± 2.55 mg in group C; P < 0.001). PONV incidence was also lower in group B (8.3% vs. 29.2% in group A and 50% in group C; P = 0.008). Conclusions: The ropivacaine and dexmedetomidine combination therapy was associated with a greater pain relief effect after sleeve gastrectomy, a greater reduction in the need to take opioids, and a lower frequency of PONV compared to the ropivacaine alone or placebo. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.